1-5 of 5
Lee H. Pai-Scherf
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC

Oladimeji Akinboro, Erin Larkins, Lee H. Pai-Scherf, Luckson N. Mathieu, Yi Ren, Joyce Cheng, Mallorie H. Fiero, Wentao Fu, Youwei Bi, Shyam Kalavar, Samina Jafri, Pallavi S. Mishra-Kalyani, Jeanne Fourie Zirkelbach, Hongshan Li, Hong Zhao, Kun He, Whitney S. Helms, Meredith K. Chuk, Min Wang, Ilynn Bulatao, Jonathan Herz, Blaire L. Osborn, Yuan Xu, Jiang Liu, Yutao Gong, Sharon Sickafuse, Rebecca Cohen, Martha Donoghue, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2221–2228.
https://doi.org/10.1158/1078-0432.CCR-21-3844
Published: 01 June 2022
View article titled, FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC
Open the PDF for FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC in another window
Journal Articles

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Janice Kim, Diana Bradford, Erin Larkins, Lee H. Pai-Scherf, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Emily Wearne, Whitney S. Helms, Amal Ayyoub, Youwei Bi, Jielin Sun, Rosane Charlab, Jiang Liu, Hong Zhao, Dun Liang, Soma Ghosh, Reena Philip, Richard Pazdur, Marc R. Theoret, Julia A. Beaver, Harpreet Singh
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5452–5456.
https://doi.org/10.1158/1078-0432.CCR-21-0967
Published: 15 October 2021
View article titled, FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <em>RET</em> Gene Mutations or Fusions
Open the PDF for FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <em>RET</em> Gene Mutations or Fusions in another window
Includes: Supplementary data
Journal Articles

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials

Marc R. Theoret, Lee H. Pai-Scherf, Meredith K. Chuk, Tatiana M. Prowell, Sanjeeve Balasubramaniam, Tamy Kim, Geoffrey Kim, Paul G. Kluetz, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4545–4551.
https://doi.org/10.1158/1078-0432.CCR-14-3244
Published: 14 October 2015
View article titled, Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials
Open the PDF for Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials in another window
Journal Articles

Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3

Lee H. Pai-Scherf, Jorge A. Carrasquillo, Chang Paik, Otto Gansow, Millie Whatley, Deb Pearson, Keith Webber, Michael Hamilton, Carmen Allegra, Martin Brechbiel, Mark C. Willingham, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (5): 1720–1730.
Published: 01 May 2000
View article titled, Imaging and Phase I Study of <sup>111</sup>In- and <sup>90</sup>Y-labeled Anti-Lewis<sup>Y</sup> Monoclonal Antibody B3
Open the PDF for Imaging and Phase I Study of <sup>111</sup>In- and <sup>90</sup>Y-labeled Anti-Lewis<sup>Y</sup> Monoclonal Antibody B3 in another window
Journal Articles

Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor

Lee H. Pai-Scherf, Jacy Villa, Deborah Pearson, Thelma Watson, Edison Liu, Mark C. Willingham, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2311–2315.
Published: 01 September 1999
View article titled, Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor
Open the PDF for Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor in another window